AR060354A1 - THROMBIN RECEPTOR ANTAGONIST COMBINATION THERAPIES (TRA) - Google Patents
THROMBIN RECEPTOR ANTAGONIST COMBINATION THERAPIES (TRA)Info
- Publication number
- AR060354A1 AR060354A1 ARP070101439A ARP070101439A AR060354A1 AR 060354 A1 AR060354 A1 AR 060354A1 AR P070101439 A ARP070101439 A AR P070101439A AR P070101439 A ARP070101439 A AR P070101439A AR 060354 A1 AR060354 A1 AR 060354A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- antagonists
- receptor antagonist
- thrombin
- thrombin receptor
- Prior art date
Links
- 239000003856 thrombin receptor antagonist Substances 0.000 title abstract 5
- 238000002648 combination therapy Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 10
- 239000005557 antagonist Substances 0.000 abstract 5
- 108010074860 Factor Xa Proteins 0.000 abstract 3
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 abstract 2
- 239000002327 cardiovascular agent Substances 0.000 abstract 2
- 229940125692 cardiovascular agent Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 abstract 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 abstract 1
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 102100037611 Lysophospholipase Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000003729 Neprilysin Human genes 0.000 abstract 1
- 108090000028 Neprilysin Proteins 0.000 abstract 1
- 102000004020 Oxygenases Human genes 0.000 abstract 1
- 108090000417 Oxygenases Proteins 0.000 abstract 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 1
- 108010058864 Phospholipases A2 Proteins 0.000 abstract 1
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 abstract 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 abstract 1
- 229960002478 aldosterone Drugs 0.000 abstract 1
- 230000000489 anti-atherogenic effect Effects 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127218 antiplatelet drug Drugs 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 abstract 1
- 229960003065 bosentan Drugs 0.000 abstract 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001906 cholesterol absorption Effects 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000002792 enkephalinase inhibitor Substances 0.000 abstract 1
- 230000003480 fibrinolytic effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 abstract 1
- 239000003119 guanylate cyclase activator Substances 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 229940127215 low-molecular weight heparin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- TUYWTLTWNJOZNY-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2h-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C2=NNN=N2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)C)C=N1 TUYWTLTWNJOZNY-UHFFFAOYSA-N 0.000 abstract 1
- 150000002823 nitrates Chemical class 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 abstract 1
- 239000002461 renin inhibitor Substances 0.000 abstract 1
- 229940086526 renin-inhibitors Drugs 0.000 abstract 1
- 229960002578 sitaxentan Drugs 0.000 abstract 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 229950000584 tezosentan Drugs 0.000 abstract 1
- 239000003868 thrombin inhibitor Substances 0.000 abstract 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen aquí composiciones farmacéuticas que comprenden por lo menos un antagonista del receptor trombina y por lo menos un agente cardiovascular. Ejemplos de dicho antagonista receptor de trombina incluyen los compuestos de formulas (1) a (3). Ejemplos de co-agentes cardiovasculares apropiados para co-formulacion o co-administracion con el antagonista del receptor trombina, incluyen un antagonista de endotelina seleccionado del grupo que consiste de tezosentan, bosentan y sitaxsentan. Reivindicacion 1: Una composicion farmacéutica que comprende: una cantidad eficaz de por lo menos un antagonista del receptor trombina; una cantidad eficaz de por lo menos un agente cardiovascular seleccionado del grupo que consiste en bloqueadores del canal de calcio, estatinas, inhibidores de absorcion de colesterol, heparinas de bajo peso molecular, agentes antiarrítmicos, agonistas alfa adrenérgicos, agentes bloqueadores beta adrenérgicos, antagonistas de aldosterona, inhibidores de la enzima convertidora de angiotensina (ôACEö), inhibidores de ACE/NEP, bloqueadores del receptor angiotensina II (ôARBsö), antagonistas de endotelina, inhibidores neutros de endopeptidasa, inhibidores de fosfodiesterasa, fibrinolíticos, antagonistas de GP lIb/lIIa, inhibidores directos de trombina, inhibidores indirectos de trombina, moduladores de fosfolipasa A2 asociada con lipoproteínas (ôLpPLA2ö) inhibidores directos del factor Xa, inhibidores indirectos del factor Xa, inhibidores indirectos de factor Xa/lla, diuréticos, nitratos, antagonistas de tromboxano, inhibidores de agregaciones de plaquetas, inhibidores de ciclooxigenasa, péptidos natriuréticos de tipo B, moduladores de NV1 FGF, antagonistas de HT1B/5HT2A, activadores de guanilato ciclasa, mejoradores de transcripcion e-NOS, anti-aterogénicos, inhibidores de CPU, inhibidores de renina, inhibidores de agregacion de plaquetas inducida por adenosina difosfato (ôADPö), e inhibidores de NHE-1, y un portador farmacéuticamente aceptable para el tratamiento de una afeccion en un mamífero.Pharmaceutical compositions comprising at least one thrombin receptor antagonist and at least one cardiovascular agent are described herein. Examples of said thrombin receptor antagonist include the compounds of formulas (1) to (3). Examples of appropriate cardiovascular co-agents for co-formulation or co-administration with the thrombin receptor antagonist include an endothelin antagonist selected from the group consisting of tezosentan, bosentan and sitaxsentan. Claim 1: A pharmaceutical composition comprising: an effective amount of at least one thrombin receptor antagonist; an effective amount of at least one cardiovascular agent selected from the group consisting of calcium channel blockers, statins, cholesterol absorption inhibitors, low molecular weight heparins, antiarrhythmic agents, alpha adrenergic agonists, beta adrenergic blocking agents, antagonists of aldosterone, angiotensin converting enzyme (ôACEö) inhibitors, ACE / NEP inhibitors, angiotensin II receptor blockers (ôARBsö), endothelin antagonists, neutral endopeptidase inhibitors, phosphodiesterase inhibitors, fibrinolytics, GP lIb / lIIa antagonists, direct thrombin inhibitors, indirect thrombin inhibitors, phospholipase A2 modulators associated with lipoproteins (ôLpPLA2ö) direct inhibitors of factor Xa, indirect inhibitors of factor Xa, indirect inhibitors of factor Xa / lla, diuretics, nitrates, thromboxane antagonists, inhibitors of platelet aggregations, cycle inhibitors oxygenase, type B natriuretic peptides, NV1 FGF modulators, HT1B / 5HT2A antagonists, guanylate cyclase activators, e-NOS transcription enhancers, anti-atherogenic, CPU inhibitors, renin inhibitors, platelet aggregation inhibitors adenosine diphosphate (ôADPö), and NHE-1 inhibitors, and a pharmaceutically acceptable carrier for the treatment of a condition in a mammal.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79046906P | 2006-04-06 | 2006-04-06 | |
| US80861106P | 2006-05-26 | 2006-05-26 | |
| US80978506P | 2006-05-31 | 2006-05-31 | |
| US83948406P | 2006-08-23 | 2006-08-23 | |
| US83947406P | 2006-08-23 | 2006-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060354A1 true AR060354A1 (en) | 2008-06-11 |
Family
ID=38458156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101439A AR060354A1 (en) | 2006-04-06 | 2007-04-04 | THROMBIN RECEPTOR ANTAGONIST COMBINATION THERAPIES (TRA) |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2001471A1 (en) |
| JP (1) | JP2009532487A (en) |
| AR (1) | AR060354A1 (en) |
| AU (1) | AU2007235353A1 (en) |
| BR (1) | BRPI0710840A2 (en) |
| CA (1) | CA2648613A1 (en) |
| MX (1) | MX2008012933A (en) |
| NO (1) | NO20084677L (en) |
| PE (1) | PE20080183A1 (en) |
| TW (1) | TW200812619A (en) |
| WO (1) | WO2007117621A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI367112B (en) * | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| EP2229173A1 (en) * | 2007-12-11 | 2010-09-22 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidinones for the treatment and/or prophylaxis of heart failure |
| CN101917990B (en) * | 2008-01-11 | 2012-11-28 | 卫材R&D管理有限公司 | Pharmaceutical composition, use of 2-iminopyrrolidine derivative for producing pharmaceutical composition, and kit for treating or improving cardiac disease |
| WO2009124103A2 (en) * | 2008-04-02 | 2009-10-08 | Schering Corporation | Combination therapies comprising par1 antagonists with par4 antagonists |
| WO2010144339A2 (en) * | 2009-06-08 | 2010-12-16 | Schering Corporation | A thrombin receptor antagonist and clopidogrel fixed dose tablet |
| US20130183392A1 (en) * | 2011-07-15 | 2013-07-18 | Steven Moore | Insect repellant and system |
| KR20140028971A (en) * | 2012-08-31 | 2014-03-10 | 한미약품 주식회사 | Bilayered tablet composite formulation of atorvastatin, irbesartan and magnesium carbonate |
| CN105125504A (en) * | 2015-09-17 | 2015-12-09 | 青岛华之草医药科技有限公司 | Composition granules of blood lipid-lowering drug pitavastatin calcium |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| NZ535880A (en) * | 2002-04-16 | 2007-11-30 | Schering Corp | Tricyclic thrombin receptor antagonists |
| US7442712B2 (en) * | 2004-05-28 | 2008-10-28 | Schering Corporation | Constrained himbacine analogs as thrombin receptor antagonists |
| EP2075250B1 (en) * | 2004-10-08 | 2015-03-04 | Merck Sharp & Dohme Corp. | Thrombin receptor antagonists |
| CA2601575A1 (en) * | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| AR058400A1 (en) * | 2005-12-22 | 2008-01-30 | Schering Corp | OXAZOLOISOQUINOLINE DERIVATIVES AS ANTHOGONISTS OF THE THROMBIN RECEPTOR |
| US20070202140A1 (en) * | 2005-12-22 | 2007-08-30 | Veltri Enrico P | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery |
-
2007
- 2007-04-04 AR ARP070101439A patent/AR060354A1/en not_active Application Discontinuation
- 2007-04-04 PE PE2007000416A patent/PE20080183A1/en not_active Application Discontinuation
- 2007-04-04 TW TW096112178A patent/TW200812619A/en unknown
- 2007-04-05 WO PCT/US2007/008612 patent/WO2007117621A1/en not_active Ceased
- 2007-04-05 BR BRPI0710840-0A patent/BRPI0710840A2/en not_active IP Right Cessation
- 2007-04-05 JP JP2009504321A patent/JP2009532487A/en not_active Withdrawn
- 2007-04-05 AU AU2007235353A patent/AU2007235353A1/en not_active Abandoned
- 2007-04-05 EP EP07755024A patent/EP2001471A1/en not_active Withdrawn
- 2007-04-05 MX MX2008012933A patent/MX2008012933A/en unknown
- 2007-04-05 CA CA002648613A patent/CA2648613A1/en not_active Abandoned
-
2008
- 2008-11-05 NO NO20084677A patent/NO20084677L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0710840A2 (en) | 2011-08-23 |
| AU2007235353A1 (en) | 2007-10-18 |
| CA2648613A1 (en) | 2007-10-18 |
| JP2009532487A (en) | 2009-09-10 |
| PE20080183A1 (en) | 2008-03-10 |
| TW200812619A (en) | 2008-03-16 |
| WO2007117621A1 (en) | 2007-10-18 |
| MX2008012933A (en) | 2008-10-15 |
| NO20084677L (en) | 2008-11-05 |
| EP2001471A1 (en) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060354A1 (en) | THROMBIN RECEPTOR ANTAGONIST COMBINATION THERAPIES (TRA) | |
| PE20211700A1 (en) | HETEROCICLIC COMPOUND AND ITS USE | |
| PE20090187A1 (en) | COMPLEX COMPOUND OF CARBON HYDRATE AND IRON | |
| AR058890A1 (en) | INTERPOLIMEROS OF ETHYLENE OF LOW MOLECULAR WEIGHT, METHODS OF REALIZATION AND USES OF THE SAME | |
| CL2012002521A1 (en) | Pharmaceutical composition comprising a dpp iv inhibitor selected from a defined group, a first diluent, a second diluent: mannitol, a second diluent: pregelatinized starch, a binder and a lubricant; Useful in the treatment of diabetes. (divisional of the sun. 1260-07). | |
| AR059977A1 (en) | CYCLOHEXIL PIPERIDINIL DIHIDROBENZIMIDAZOL COMPOSITION PHARMACEUTICAL COMPOSITION INCLUDED IN ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT PROCESS FOR PREPARATION AND INTERMEDIARY COMPOUND FOR THE SYNTHESIS OF THE SAME | |
| CL2011000402A1 (en) | Compounds derived from 1- {4-fluoro-5- (2-fluoropyridin-3-yl) -1 - [(4-methylpyridin-2-yl) sulfonyl] -1h-pyrrol-3-yl} -n-methylmethanamine and 1- {4-fluoro-5- (2-fluoropyridin-3-yl) -1 - [(4-methoxypyridin-2-yl) sulfonyl] -1h-pyrrol-3-yl} -n-methylmethanamine; pharmaceutical composition; and use in the treatment of peptic ulcer, gastric cancer among others. | |
| BR112013030592A2 (en) | absorbent structure for absorbent articles | |
| AR078490A1 (en) | SPECIFIC INHIBITORS MONOCLONAL ANTIBODIES OF THE FIBRINOGEN UNION / MAC-1 | |
| CO6420358A2 (en) | QUICK DRYING POLYMER COATING | |
| PE20050471A1 (en) | THROMBINE RECEPTOR ANTAGONISTS | |
| AR064735A1 (en) | GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND | |
| EA201170304A1 (en) | GLUOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES | |
| EP2235523A4 (en) | SYSTEMS, METHODS, AND COMPUTER-READABLE MEDIA FOR DETERMINING THE COMPOSITION OF CHEMICAL CONSTITUENTS IN A COMPLEX MIXTURE | |
| AR094588A2 (en) | PROCESS FOR OBTAINING A COMPOSITE DERIVED FROM BENZIMIDAZOL AND PHARMACEUTICAL COMPOSITION | |
| CL2008003511A1 (en) | Nucleotide derived compounds, hepatitis c virus ns5b polymerase inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c. | |
| CL2008002369A1 (en) | Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer. | |
| CL2008003600A1 (en) | Compound (e) -n- (5 - [(e) -3-fluoro-6h-dibenzo [b, e] oxepin-11-ylidenemethyl) -1 - ((r) -1-methyl-2-morpholin-4 -yl-ethyl) -1,3-dihydro-benzimidazol-2-ylidene) -urea, its salts, nonsteroidal mineralocorticoid receptor antagonist; pharmaceutical composition; and use to treat congestive heart failure and diabetic nephropathy, among others. | |
| PE20091732A1 (en) | SUBSTITUTED DIHYDROPIRAZOLONES AND THEIR USE | |
| AR055570A1 (en) | OXAZOL POLYMORPH - PIRROLIDINE, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS. | |
| BR112014012114A8 (en) | psa containing olefin block copolymers and styrene block copolymers | |
| ECSP088592A (en) | AGONIST DIMMER COMPOUNDS OF FGF RECEIVERS (FGFR) | |
| EP2480077A4 (en) | NOVEL PYRROLIDINES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF | |
| BRPI0812645A2 (en) | "COMPOSITION AND PROCESS FOR FORMING MOISTURE-CURED ARTICLE" | |
| CL2008003266A1 (en) | Compounds derived from cycloguanidine substituted pyrimidinedione and triazinedione, useful as a prokineticin receptor antagonist; pharmaceutical composition comprising said compounds; and use in the treatment of gastrointestinal diseases. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |